“…Patients are commonly classified as ultra extensive metabolizers, extensive metabolizers, intermediate metabolizers, or poor metabolizers, based on their number of copies of functional CYP2D6 allele. [41] The Cyp2D6*10 allele is one of the most important Cyp2D6 variants with reduced enzymatic activity, which are referred to as residual functional alleles. As individuals with homozygous mutant genotypes of this allele are usually intermediate or poor metabolizers, it has been suggested that they will be more sensitive to BBs.…”